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Abstract 
This insert represents a review of myeloid and 
lymphoid neoplasms with abnormalities of 
PDGFRA including clinical presentation, 
morphologic review, and cytogenetic findings. 
KEYWORDS 
Myeloid and lymphoid neoplasms with 
abnormalities of PDGFRA; PDGFRA; CHIC2; 
eosinophilia; chronic eosinophilic leukemia; 
tyrosine kinase inhibitor 
Identity 
Myeloid/Lymphoid neoplasms with abnormalities of 
PDGFRA 
Clinics and pathology 
Disease 
Myeloid and lymphoid neoplasms with 
abnormalities of PDGFRA are neoplasms in which 
eosinophilia is highly typical, although not required. 
For years, most patients with eosinophilia and 
abnormalities of PDGFRA were diagnosed with 
hypereosinophilic syndrome (HES) as karyotype 
was frequently normal and no secondary cause was 
identified. However, in 2001, a subset of patients 
with HES were found to show responsiveness to 
tyrosine kinase inhibitors (TKI), specifically 
imatinib. Investigation of the tyrosine kinases within 
these patients revealed a cryptic deletion resulting in 
fusion of PDGFRA to FIP1L1. After this 
groundbreaking research, the entity was first 
formally accepted in the 2008 edition of the World 
Health Organization's Classification of Tumours of 
Haematopoietic and Lymphoid Tissues along with 
abnormalities of PDGFRB and FGFR1. In the WHO 
2016 edition, myeloid and lymphoid neoplasms with 
eosinophilia and t(8;9)(p22;p24.1) PCM1 / JAK2 is 
now recognized as a provisional entity. 
Phenotype/cell stem origin 
The cell of origin is a hematopoietic cell with 
commitment to eosinophilic differentiation. These 
clonal eosinophils may show evidence of activation 
by immunohistochemistry, with CD23, CD25, 
and/or CD69 expression. 
Epidemiology 
There is an overwhelming male predominance with 
a median age of onset of 40-years-of age, although 
they may present across a broad age range. 
Clinics 
Patients with hematopoietic neoplasms involving 
PDGFRA often present with fatigue or pruritic rash. 
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Multi-organ tissue damage, including respiratory, 
gastrointestinal, or cardiac sequelae, is well reported 
due to tissue infiltration by clonal eosinophils. 
Physical examination reveals splenomegaly in most 
patients and hepatomegaly within a minority. 
Peripheral blood smear traditionally shows features 
suggestive of chronic eosinophilic leukemia (CEL). 
Although abnormalities of PDGFRA usually 
resemble CEL, rarely, patients may display 
characteristics of acute myeloid leukemia (AML) or 
T-cell lymphoblastic leukemia/lymphoma (T-
ALL/LBL). However, eosinophilia traditionally 
remains a consistent feature. 
Pathology 
In patients with abnormalities of PDGFRA, 
eosinophilic atypia may be present (Figure 1), but is 
variable and not required. This includes atypical 
nuclear segmentation, hypogranular cytoplasm with 
puddling of eosinophilic granules, more variability 
in granule texture/color, and cytoplasmic 
vacuolation. Eosinophils are typically mature with 
usually only rare eosinophilic precursors noted 
(Figure 2). Anemia and thrombocytopenia are 
common, while monocytosis and basophilia are 
infrequent (Savage et al., 2013). 
Bone marrow trephine biopsies are typically 
hypercellular with increased eosinophils and their 
precursors (Figure 3) (Bain et al., 2008). Fibrosis 
may also be increased and can be highlighted with a 
reticulin histochemical stain (Figure 4). Mast cells 
are often increased as well, either in loose or 
cohesive clusters, and may have atypical spindled 
morphology. Moreover, they may have an aberrant 
immunophenotype, frequently expressing CD25 or 
even CD2 and CD25. However, the findings usually 
fall short of criteria for systemic mastocytosis as KIT 
D816V mutation is not present and serum tryptase 
levels are typically less than 20 ng/mL. 
 
In this smear obtained from a patient with PDGFRA abnormality, eosinophilia is noted with some atypical 
morphology. Specifically, granules unevenly fill the cytoplasm with one eosinophil having few cytoplasmic 
vacuoles. In addition, the nuclear segmentation is atypical with increased nuclear lobes noted in one eosinophil. 
(Wright Giemsa stained peripheral blood smear, original magnification 500x). 
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Here an immature eosinophil is noted (eosinophilic myelocyte) with uneven granule distribution; moreover, the 
granules appear more fine than typical for an eosinophilic precursor. (Wright Giemsa stained peripheral blood 
smear, original magnification 1000x). 
 
 
The bone marrow is hypercellular due numerous eosinophilic precursors. (Hematoxylin and Eosin stained bone 
marrow biopsy, original magnification 500x). 
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Reticulin histochemical stain highlights increased bone marrow fibrosis. (Reticulin histochemical stain of bone 
marrow biopsy, original magnification 500x). 
Treatment 
Patients with abnormalities of PDGFRA are 
exquisitely sensitive to imatinib. An initial dose of 
100 mg per day leads to complete hematologic 
response in most patients. If imatinib is discontinued 
secondary to adverse reactions or very rarely due to 
resistance, it can be replaced by second or third 
generation TKI. 
Prognosis 
Prior to identification of this neoplasm with response 
to TKI, prognosis was poor. However, now while on 
maintenance therapy, >90% of patients will achieve 
complete molecular response. Prognosis is excellent 
particularly if therapy is initiated prior to organ 
damage especially cardiac sequela. 
Cytogenetics 
Cytogenetics morphological 
Although a number a fusion partners for PDGFRA 
have been identified (Table 1), the most common by 
far is FIP1L1 (Bain et al., 2008). The FIP1L1-
PDGFRA fusion gene is created by an interstitial 
deletion on chromosome 4q12 (Cools et al., 2003); 
this deletion includes cysteine-rich hydrophobic 
domain 2 ( CHIC2) (Pardanani et al., 2003). The 
deletion is most often cryptic resulting in a normal 
karyotype, necessitating FISH for identification 
(Figure 4). However, rarely it may be caused by 
chromosomal rearrangement. .  
Fusion partner genes and locations 
FIP1L1 4q12 
BCR 22q11 
ETV6 12p13 
STRN 2p22 
CDK5RAP2 9q33 
KIF5B 10p11 
FOXP1 3p13 
Table 1.  Myeloid and lymphoid neoplasms with 
eosinophilia and abnormalities of PDGFRA - 
reported fusion partners. 
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FIP1L1 (green), CHIC2 (red), and PDGFRA (aqua) 
probes reveal nuclei with one intact 
FIP1L1/CHIC2/PDGFRA signal and one signal with 
FIP1L1/PDGFRA indicating CHIC2 deletion. 
(PDGFRA FISH; photo courtesy of Dr. Robert 
Jenkins of the Mayo Clinic) 
Genes involved and 
proteins 
PDGFRA (platelet-derived growth 
factor receptor, alpha polypeptide) 
Location 
4q12 
Note 
Platelet Derived Growth Factor Receptor Alpha 
(PDGFRA) is located on chromosome 4, band q12. 
It contains 23 exons and spans approximately 65 kb. 
The encoded protein is 1089 amino acids with 
molecular weight of 122670 Da. It is inactive as a 
monomer in the absence of bound ligand. It is a 
member of the type III class of tyrosine kinase 
receptors. It contains 5 immunoglobulin-like 
extracellular domains, a single transmembrane 
domain, and an intracellular split kinase domain. The 
protein plays an essential role in the regulation of 
many biological processes which include cell 
proliferation, differentiation, migration, and 
survival. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
The most common fusion gene produced is the 
FIP1L1-PDGFRA, which is due to a deletion 
involving the intervening CHIC2 gene (~800 kb 
interstitial chromosomal deletion), which is 
frequently cryptic via conventional karyotyping. 
This results in an activated tyrosine kinase that 
transforms hematopoietic cells from constitutive 
activation of PDGFRA. 
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